Medicamen Biotech Limited (IN:MEDICAMEQ)

:MEDICAMEQ

MEDICAMEQ

Medicamen Biotech Limited

RESEARCH TOOLSreports

Medicamen Biotech Limited (MEDICAMEQ) Price & Analysis

0 Followers

MEDICAMEQ Stock Chart & Stats

₹366.90

-₹10.20(-1.97%)

At close: Jan 08 4:00 PM EST

₹366.90

-₹10.20(-1.97%)

Day’s Range― - ―

52-Week Range₹220.00 - ₹510.00

Previous CloseN/A

Volume10.37K

Average Volume (3M)2.40K

Market Cap

₹3.07B

Enterprise Value₹3.01B

Total Cash (Recent Filing)₹436.79M

Total Debt (Recent Filing)₹386.49M

Price to Earnings (P/E)56.5

Beta1.56

Next Earnings

Jun 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.26%

Share Statistics

EPS (TTM)1.61

Shares Outstanding13,562,815

10 Day Avg. Volume3,620

30 Day Avg. Volume2,395

Financial Highlights & Ratios

PEG Ratio-2.50

Price to Book (P/B)2.95

Price to Sales (P/S)3.86

P/FCF Ratio-52.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Stable Balance Sheet And Moderate LeverageA solid balance sheet with reasonable debt-to-equity and a strong equity ratio supports long-term solvency and financial flexibility. This structural strength gives the company capacity to fund operations, absorb shocks, and pursue opportunistic investments without immediate refinancing pressure.

Healthy Operating Margins (EBIT/EBITDA)Relatively healthy EBIT/EBITDA margins indicate the business converts revenue to operating profit effectively, reflecting durable cost controls and operational discipline. Sustained margin strength supports internal funding for R&D, manufacturing upkeep, and competitive pricing over the medium term.

Diversified Formulation Sales (domestic + Export) And Manufacturing CapabilityA business model that sells finished dosages domestically and to export markets provides structural diversification across geographies and customer types. Manufacturing capability supports own-brand sales and potential contract manufacturing, lowering reliance on any single market or buyer over months.

Bears Say

Negative Operating And Free Cash FlowPersistent negative operating and free cash flow undermines the firm's ability to self-fund working capital, capex, or pay down debt. Over a 2–6 month horizon this creates structural liquidity risk and increases probability of needing external financing, diluting strategic flexibility.

Inconsistent Revenue Growth And Volatile Net MarginIrregular top-line trends and volatile net margins make planning and scale-up difficult and raise earnings predictability risk. This structural variability can limit reinvestment, complicate supplier/partner negotiations, and increase sensitivity to demand swings over the medium term.

Operating In Competitive Specialty & Generic PharmaThe specialty and generic pharmaceuticals sector is structurally competitive with pricing pressure and product commoditization. Without clear differentiation or scale, sustaining margins and growth is harder, making the company more exposed to price competition and customer consolidation over months.

Medicamen Biotech Limited News

Medicamen Biotech Gets NSE Caution Over Compliance Observations

The latest announcement is out from Medicamen Biotech Limited ( ($IN:MEDICAMEQ) ). Medicamen Biotech Limited has disclosed that...

2M ago

MEDICAMEQ FAQ

What was Medicamen Biotech Limited’s price range in the past 12 months?

Medicamen Biotech Limited lowest stock price was ₹220.00 and its highest was ₹510.00 in the past 12 months.

What is Medicamen Biotech Limited’s market cap?

Medicamen Biotech Limited’s market cap is ₹3.07B.

When is Medicamen Biotech Limited’s upcoming earnings report date?

Medicamen Biotech Limited’s upcoming earnings report date is Jun 03, 2026 which is in 56 days.

How were Medicamen Biotech Limited’s earnings last quarter?

Medicamen Biotech Limited released its earnings results on Feb 13, 2026. The company reported ₹1.613 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.613.

Is Medicamen Biotech Limited overvalued?

According to Wall Street analysts Medicamen Biotech Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medicamen Biotech Limited pay dividends?

Medicamen Biotech Limited pays a Notavailable dividend of ₹1 which represents an annual dividend yield of 0.26%. See more information on Medicamen Biotech Limited dividends here

What is Medicamen Biotech Limited’s EPS estimate?

Medicamen Biotech Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medicamen Biotech Limited have?

Medicamen Biotech Limited has 13,562,815 shares outstanding.

What happened to Medicamen Biotech Limited’s price movement after its last earnings report?

Medicamen Biotech Limited reported an EPS of ₹1.613 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.671%.

Which hedge fund is a major shareholder of Medicamen Biotech Limited?

Currently, no hedge funds are holding shares in IN:MEDICAMEQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medicamen Biotech Limited

Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, and ointments. It also provides oral rehydration solution, mouth wash, and dental care products. The company was incorporated in 1993 and is based in New Delhi, India.